Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

regarding the role of carvedilol in preventing hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension (CSPH) stratified by a new non-invasive model. 2 Identifying predictors of decompensation in compensated patients is crucial, as the onset of decompensation is closely linked to mortality in cirrhosis. 3The hepatic venous pressure gradient (HVPG) is the gold stan-dard for assessing portal pressure and the foremost predictor of decompensation in cirrhotic patients. 4,5As noted in the editorial, however, the invasive procedure and restricted accessibility of HVPG measurements impede its widespread use.Due to this reason, non-invasive tests are extensively employed to detect CSPH in patients with compensated cirrhosis.The Baveno VII criteria provide specific thresholds for ruling in CSPH if liver stiffness measurement (LSM) 25 kPa or out if LSM15 kPa plus platelet count (PLT) 15010 9 /L, yet a grey zone exists for patients whose test results fall between these thresholds. 6In such cases, the ANTICI-